Teva has issued a voluntary recall for its intravenous cancer medicine Adrucil because of the potential presence of impurities.
As Philadelphia Business Journal reported, Teva recalled six lots of Adrucil because they may contain small amounts of silicone rubber pieces and fluorouracil crystals. In May, it recalled eight lots of the cancer medicine for the same reason.
No adverse events have been reported, but a company statement on the FDA website said “administration of an intravenous product with particulate matter has the potential to result in inflammation, allergic reactions, or blockage of blood vessels, leading to tissue death, which may be life-threatening if vital organs are affected.”
http://www.phillyvoice.com/teva-recalls-cancer-drug-second-time/
